Previous studies from our laboratories have shown that transgenic mice expressing high levels of PS globin are wellprotected from Plasmodium chabaudi adami and partially protected against PbergheiGhear et al. Blood81:222,1993). We have now infected transgenic mice expressing low (39%). intermediate (57%). and high (75%) levels of PS with the virulent strain of P yoelii (17XL) that appears to cause cerebral malaria. We find that the level of protection in these three groups of mice correlates positively with the level of PS chain expression in the mice. Seven of nine mice expressing the high level of PS recovered from infection, as did 7 of HE POLYMORPHIC frequency of the gene for p', which is involved in the generation of sickle trait and sickle cell anemia in humans, is thought to be due to the reduced risk to sickle trait individuals of dying from Plasmodium falciparum malaria (reviewed in Nagel and Roth'). Both and in vitro studies4,' support this idea. Sickle trait-infected erythrocytes were found to sickle faster than noninfected sickle trait red blood cells (RBCs) at physiologically reduced oxygen tensionsh as well as in venous bl00d.~ It was found that the pH of infected normal RBCs is 0.4 U lower than that of noninfected erythrocytes.x This decrease in pH, coupled with normal deoxygenation, is sufficient to cause sickling of some of the infected sickle trait RBCs and their removal by the spleen (suicidal infection). Further deoxygenation also impairs the growth of the parasites in AS Cerebral malaria (CM) refers to one of the most severe sequelae of falciparum malaria in which vascular plugging of infected erythrocytes in the brain can lead to coma and death? Estimates vary widely; however, it is clear that many deaths from malaria are due to CM (reviewed in Warrell et all"). The precise mechanisms underlying CM are not completely understood. Cytoadherence of the mature stages of the parasite to the vascular endothelial cells is thought to be largely responsible for the phenomenon."
tects them from CMi2 and some epidemiologic evidence supports the contention," although the mechanisms by which this might occur are not fully understood. The deoxygenation of infected erythrocytes in the internal organs probably leads to sickling of RBCs containing young parasites (rings and early trophozoite^),",^ recognition by splenic macrophages, and removal. In support of this hypothesis is the observation that the protective effect of sickle trait is most obvious at 2 to 4 years of age, when the spleen becomes fully effective."
Cytoadherence to the endothelium of the mature stages (older trophozoites and schizonts) leads to sequestration of parasitized RBCs in the internal organs such as the brain and prevents the mature stages from passage through the spleen and destruction by splenic macrophages. However, after cytoadherence, sickle trait cells are at risk of profound deoxygenation due to stasis. As discussed above, studies with cultured parasitized erythrocytes suggest that deoxygenation of sickle trait RBCs inhibits the growth of the parasite.J.5 It may also lead to sickling and death of the parasites. In addition, recent data suggest that impaired rosette formation may also play a role in the resistance of sickle trait individuals to CM. '5 Direct experimental evidence of the protective effect of PS gene expression against CM has been lacking because of the absence of suitable animal models for both CM and sickle trait. We have recentlyprovided evidence of the suitability of P yoelii 17XL infection in mice as a model for CM.I6.l7 We have shown that P goelii 17XL causes obstruction in the mouse brain in the absence of marked inflammati~n.'~ Microscopic observations of the cremaster microcirculatory flow in these animals showed cytoadherence of erythrocytes to the endothelium of postcapillary venule^.'^ The generation of transgenic mice expressing high levels of human PS and human a chains'* has allowed US to study the mechanisms of the protection of PS against malaria in vivo. We found that these transgenic mice are well protected from P chahaudi adarni, a nonlethal rodent malaria," whereas transgenic mice expressing normal human p" chain are fully susceptible to this parasite.*' A small but significant level of protection against P herghei, a lethal infection, was also observed.") Nevertheless, to fully prove the hypothesis that sickle trait protects the host against cerebral malaria, we needed to show protection against CM at levels of PS expression closer to those found in sickle trait individuals. yoelii 17XL has provided the proper model to study this phenomenon in vivo. Thus, in the current study, we investigated the role of sickle hemoglobin in protection against CM by infecting mice expressing varying levels of PS, ie, low (39%), intermediate (56%), and high (75%), with P yoelii 17XL, which causes CM in
MATERIALS AND METHODS
Animals and infection with malaria parasires. C57BL/6J female mice (6 to 8 weeks old) were obtained from the Jackson Laboratories (Bar Harbor, ME). SW mice (females; 6 to 8 weeks old) were from Taconic Farms (Germantown, NY). Development of the transgenic mice was described previously.'* Briefly, these mice were produced by coinjection of two constructs each containing a mini-LCR (locus control region) and either the human a2-or Ps-globin genes into fertilized eggs of strain FVBN. The mini-LCR contained the 5' hypersensitive sites (I-IV) of the human P-globin locus control region. One transgenic line carrying both human globin genes was obtained (aHpS-ll). Animals in this line expressed 39.0% ? 1.4%
Ps-chains, and 53.3% of all chains were P (Table l) , with a ratio of human a-(cyH) to P-chain of 1.35. These mice were bred with mice homozygous for a P major deletion on a C57BW6J background:' and the progeny, which were heterozygous for the P major deletion, (aHpS[pMu]; mouse deletion [MD]), expressed 57.6% ? 1.0% PS chains with a human a"-to Ps-ratio of 1 and 51.4% total &chains. Transgenic mice that were bred to homozygosity for the P major deletion, (aHPs[[PMuu]), expressed 75.5% 2 2.1% PS chains, but the aH-to PS-ratio decreased to 0.73. These mice had a normal hematocrit level and a slightly elevated percentage of reticulocytes (6.7% reticulocytes compared with 5.2 % in FVBN and 3.4% in C57BL/6J).Mice expressing low levels of PS had normal reticulocyte levels. The mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) of the controls and three experimental groups is also shown in Table 1 . There were no significant differences in the MCV or MCH among the groups, indicating that none of the groups were phenotypically thalassemic. Mice were bred at the Albert Einstein College of Medicine in an American Association of Accredited Laboratory Animal Care (AAALAC)-accredited facility.
The globin composition was determined by high-performance liquid chromatography (HPLC) using a denaturing solvtnt that separates the globin chains and a Vydac large-pore (300A) C,, column (4.6 X 250 mm; Separations Group, Hesperia, CA) with a modified acetonitrile/H20/trifluoroacetic acid (TFA) gradient similar to that used by Schroeder et alZZ for separating human chains. Two buffers were used, A (0.18% TFA in 36% acetonitrile) and B (0.18% TFA in 46% acetonitrile). Starting with 38% B, the percentage of B was increased by 0.583%/min until all of the globin chains were eluted.
P yoelii 17XL (lethal) stored in liquid nitrogen was used to infect source mice. Experimental mice were infected by intraperitoneal inoculation of 10' infected erythrocytes obtained from a source mouse. Parasitemia was monitored by making smears of blood obtained from the tail vein and counting 50 Giemsa-stained fields or at least 300 RBCs under oil immersion (1,OOOx). The statistical significance of the data was assessed by comparing mean parasitemia of groups of mice at particular time points using the Student's ttest.
RESULTS
Transgenic mice expressing high levels of human and a-chains are protected from P yoelii 17XL. In a preliminary experiment, we found that three of four mice expressing high levels of sickle hemoglobin recovered from infection with P yoelii 17XL, whereas all ( M ) the control C57BW6J mice succumbed to infection. Parasitemia of the transgenic mice was significantly lower than that of the control mice from day 4 on (P < .OS; data not shown). in the groups of mice at several time points during infection. Parasitemias of mice in the high level group were significantly lower than those of controls on days 5 and 7 (P < .01) and were significantly lower than those of the intermediate mice on day 5 (P < .05). After day 5, the parasitemia of the intermediate mice varied considerably so that a statistical difference with the high level mice was not observed.
Protection against P yoelii
Interestingly, during recovery in both the intermediateand high-level PS groups, parasites were confined almost exclusively to the reticulocytes, whereas in the early phase . .
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of infection and in the control mice throughout the infection, parasites were found predominantly in mature erythrocytes.
As shown in Fig 3A, on day 5 of infection in a mouse expressing the high level of PS, 10% of the mature erythrocytes were infected compared with 0.3% of reticulocytes. Figure 3B is a blood smear taken on day 9 of infection of the same mouse. Here, 81% of reticulocytes are infected compared with 1.3% of mature RBCs.
It should be noted that, during recovery, the level of reticulocytes reached 45%. Blood from the recovering mice, containing infected reticulocytes, was transferred to normal SW mice and the course of infection followed. In the SW mice, the parasites invaded mature RBCs and the mice succumbed to infection within 1 week (data not shown).
DISCUSSION
In previous studies, we showed that mice expressing high levels of Ps-chains were protected from P chabaudi adami but less so from P bergf~ei.'~ Further evidence that the expression of human p" is responsible for the protection seen in the transgenic mice comes from the quantitative correlation of expression of PS with increased levels of protection against P yoelii 17XL (Figs 1 and 2) .
Importantly, P yoelii 17xL, the malaria species used in these studies, appears to cause CM in mice. We show here that PS globin protects mice from the strain of parasite that causes CM. The brain of an infected mouse It was not clear from our earlier studies of the PStransgenic mouse line whether the greater protection of mice from P chubuudi udarni than from P berghei was due to the greater virulence of P berghei or to some other factor.1g In this study, we show that the PS transgenic mice are resistant to the highly virulent strain of P yoelii 17XL, indicating that the greater virulence of P berghei was probably not the cause of the diminished protection in PS mice.
Although the strain of P yoelii used in this study usually invades mature RBCs, we observed that, in the recovering mice, parasites were confined almost entirely to reticulocytes (Fig 3) . This finding suggests that the maturational stage of the erythrocyte determines the degree of resistance afforded by the PS chain. Thus, transgenic mice were probably less protected from P berghei because this parasite preferentially invades reticulocytes. Reticulocytes have the lowest mean corpuscular hemoglobin concentration (MCHC) of all circulating RBCs. They are thus less prone to sickling because the delay time of polymerization varies inversely with the 32nd power of the concentration of hemoglobin S at the start of the reaction.24 Thus, reduced sickling in reticulocytes may permit better survival of the malaria parasite. Furthermore, these results suggest a potential explanation for the fact there is no evidence for the protection of individuals from P vivax, which also invades less mature RBCS.*~
In conclusion, the development of transgenic mice expressing human PS-and a"-genes has allowed investigations in vivo into the mechanisms of protection of sickle trait against malaria. Experimental evidence for the protection of carriers of sickle trait from cerebral malaria has been obtained. This model will allow further studies into the mechanisms of protection, particularly with the use of strains of rodent malaria that differ in virulence and erythrocyte specificity.
